{
    "2018-05-15": [
        [
            {
                "time": "2018-04-20",
                "original_text": "AstraZeneca’s 1Q18 Earnings: Analysts’ Estimates",
                "features": {
                    "keywords": [
                        "AstraZeneca",
                        "1Q18",
                        "Earnings",
                        "Analysts",
                        "Estimates"
                    ],
                    "sentiment_score": 0.6,
                    "policy_related": "false",
                    "investment_strategy": "true",
                    "sector_focus": [
                        "pharmaceuticals"
                    ],
                    "causal_factor": "true",
                    "causal_impact": "positive",
                    "affected_by_time_series": "false",
                    "ts_effect_direction": "neutral"
                }
            },
            {
                "time": "2018-03-15",
                "original_text": "ADRU's Holdings Could Mean 10% Gain Potential",
                "features": {
                    "keywords": [
                        "ADRU",
                        "Holdings",
                        "Gain",
                        "Potential"
                    ],
                    "sentiment_score": 0.75,
                    "policy_related": "false",
                    "investment_strategy": "true",
                    "sector_focus": [
                        "diversified"
                    ],
                    "causal_factor": "false",
                    "causal_impact": "neutral",
                    "affected_by_time_series": "true",
                    "ts_effect_direction": "positive"
                }
            }
        ]
    ]
}